scispace - formally typeset
E

Elliott M. Antman

Researcher at Brigham and Women's Hospital

Publications -  738
Citations -  187175

Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.

Papers
More filters
Journal ArticleDOI

Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin

Michael P. Thomas, +10 more
- 10 Feb 2012 - 
TL;DR: No significant relationship between aPTT values and recurrent ischemic events or major bleeding was found and the required intensity of anticoagulation for benefit may be relatively modest when UFH is administered concomitantly with dual or triple platelet-directed therapy, particularly in patients undergoing early coronary revascularization.
Journal ArticleDOI

Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction.

Amir Kashani, +6 more
- 15 Jan 2005 - 
TL;DR: The use of coronary angiography and clinical outcomes among patients who had heart failure and were enrolled in the Intravenous Novel Plasminogen Activator (NPA) for the Treatment of Infarcting Myocardium Early study are evaluated.
Journal ArticleDOI

Safety and efficacy of unfractionated heparin vs. enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies☆

Sarah A. Spinler, +5 more
- 01 Sep 2003 - 
Journal Article

Abstract 16534: Cost-Effectiveness of Edoxaban vs. Warfarin in Patients With Atrial Fibrillation: Results From the ENGAGE AF - TIMI 48 Economic Study

Elizabeth A. Magnuson, +8 more
- 25 Nov 2014 - 
TL;DR: It is suggested that HD E is a high economic value therapeutic alternative relative to W for the prevention of stroke and SE in patients with AF and low dose E is likely to offer intermediate value from an economic perspective.
Journal ArticleDOI

Cardiac troponin T and point-of-care testing for myocardial infarction.

Elliott M. Antman, +1 more
- 01 Nov 1995 - 
TL;DR: To the Editor —Despite their obvious enthusiasm for point-of-care testing for cardiac troponin T (cTnT), Dr Antman and colleagues have not provided convincing evidence that this technology is either applicable or appropriate in the clinical setting.